Compare Vanguard Mega Cap Growth ETF (MGK) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs Summit Therapeutics Inc — how do they compare? Vanguard Mega Cap Growth ETF trades at $87.34, while Summit Therapeutics Inc trades at $13.68 (market cap $10.48B). The key difference: Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| MGK | SMMT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $92.06 | $29.32 |
52-Week Low | $70.70 | $13.05 |
Market Cap | — | $10.48B |
Enterprise Value | — | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK, the Vanguard Mega Cap Growth ETF, trades at $86.83 with no recent price change. The technical outlook is bearish based on moving averages, while oscillators are neutral. Recent news highlights its low expense ratio of 0.05% and concentrated portfolio of 69 large-cap growth stocks, including heavy exposure to technology leaders. A 1:5 stock split occurred on April 21, 2026, and a small dividend is scheduled for June 2026.
MGK offers exposure to top U.S. growth companies but faces risks from high concentration in tech stocks and market volatility. Its long-term performance history and cost efficiency present opportunities for growth-focused investors, though sector-specific downturns could impact returns significantly.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
